Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | SELE | P16581 | 1/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724781 | 0.85 | GCK (0.65) | GCKALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL1722285 | 0.84 | GCK (0.66) | GCKMAPTNPSR1ICAM1SELE | |
| SCHEMBL9989531 | 0.81 | GCK (0.66) | GCKALDH1A1SMN1; SMN2 | |
| SCHEMBL1725540 | 0.80 | GCK (0.67) | GCK | |
| SCHEMBL1726599 | 0.79 | HSD17B2 (0.48) | GCKALDH1A1ADORA3NPSR1JMJD6 | |
| SCHEMBL1724761 | 0.76 | GCK (0.46) | GCKALDH1A1NPSR1 | |
| SCHEMBL1724129 | 0.76 | GCK (0.46) | GCKALDH1A1NPSR1JMJD6 | |
| SCHEMBL1722265 | 0.75 | CYP1A2 (0.51) | ALDH1A1ADORA3NPSR1JMJD6 | |
| SCHEMBL1722207 | 0.74 | GCK (0.69) | GCK | |
| SCHEMBL644821 | 0.74 | GCK (0.49) | GCKALDH1A1HPGDSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406230-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103438-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103438-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | GCKR, GCK, GALK1 | GCK 2/4885ALDH1A1 1454/4885ADORA3 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.